Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in women with a history of recurrent urinary tract infection: a 6-month multicentre, randomised, double-blind, placebo-controlled trial
Abstract
Urinary tract infections (UTI) are amongst the most common bacterial infections worldwide, posing significant clinical and economic burden(1). Women are more susceptible, with nearly 50–60% of women experiencing at least one UTI during their lifetime, and 30–40% experiencing recurrent UTI (rUTI) in their lifetime(1). Cystitis, the most common UTI, remains one of the most common indications for prescribing antimicrobial treatment. However, continued use is associated with antimicrobial resistance(2), a major concern to health care and economic burden. Establishing alternative safe and effective non-antibiotic therapies for prevention of rUTI in otherwise healthy women is therefore important. Cranberry-containing products have been shown to reduce risk of UTIs(3) through inducing anti-adhesive activity against uropathogenic Escherichia coli to uroepithelial cells(4). Most clinical trials to date have tested fractions from cranberry fruit, such as juice concentrate or isolated proanthocyanidins(3). This study investigated the effect of a whole cranberry fruit powder supplement on incidence of culture-confirmed UTI (primary outcome) in women with rUTI history. A multicentre, 6-month, randomised, placebo-controlled, double-blind study enrolled 150 healthy females (18–65 years, body mass index (BMI) > 17.5- 5 UTIs in the last 6 months were excluded. Eligible participants were randomised to 1 capsule of either 500 mg/day whole cranberry powder (Swisse High Strength Cranberry…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.